🚀 VC round data is live in beta, check it out!
Genscript Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Genscript Biotech and similar public comparables like Diasorin, Brightgene Bio-medical, Sotera Health, MGI Tech and more.
Genscript Biotech Overview
About Genscript Biotech
Genscript Biotech Corp is a China-based provider of life science research services and products. The firm is known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. The company's business segments include Life-science services and products, Biologics development services, Industrial synthetic biology products, and the Operation unit. The company generates the majority of its revenue from the life-science services and products unit, which provides comprehensive research services and products, which are widely used and are fundamental to life-science research and application. Geographically, the company generates the majority of its revenue from the United States of America, followed by Mainland China.
Founded
2002
HQ
Employees
5.6K
Website
Financials (LTM)
EV
$3B
Genscript Biotech Financials
Genscript Biotech reported last 12-month revenue of $916M and EBITDA of $169M.
In the same LTM period, Genscript Biotech generated $585M in gross profit, $169M in EBITDA, and had net loss of ($356M).
Revenue (LTM)
Genscript Biotech P&L
In the most recent fiscal year, Genscript Biotech reported revenue of $960M and EBITDA of $188M.
Genscript Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $916M | XXX | $960M | XXX | XXX | XXX |
| Gross Profit | $585M | XXX | $553M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $169M | XXX | $188M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 20% | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | ($356M) | XXX | ($533M) | XXX | XXX | XXX |
| Net Margin | (39%) | XXX | (56%) | XXX | XXX | XXX |
| Net Debt | — | — | $52M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Genscript Biotech Stock Performance
Genscript Biotech has current market cap of $4B, and enterprise value of $3B.
Market Cap Evolution
Genscript Biotech's stock price is $1.76.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $4B | 0.0% | XXX | XXX | XXX | $-0.24 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGenscript Biotech Valuation Multiples
Genscript Biotech trades at 3.6x EV/Revenue multiple, and 19.5x EV/EBITDA.
EV / Revenue (LTM)
Genscript Biotech Financial Valuation Multiples
As of April 19, 2026, Genscript Biotech has market cap of $4B and EV of $3B.
Equity research analysts estimate Genscript Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genscript Biotech has a P/E ratio of (10.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 3.6x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | 19.5x | XXX | 17.5x | XXX | XXX | XXX |
| EV/EBIT | 16.2x | XXX | 12.5x | XXX | XXX | XXX |
| EV/Gross Profit | 5.6x | XXX | 5.9x | XXX | XXX | XXX |
| P/E | (10.8x) | XXX | (7.2x) | XXX | XXX | XXX |
| EV/FCF | 23.1x | XXX | 13.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Genscript Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Genscript Biotech Margins & Growth Rates
Genscript Biotech's revenue in the last 12 month declined by (7%).
Genscript Biotech's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Genscript Biotech's rule of 40 is 0% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Genscript Biotech's rule of X is (23%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Genscript Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (7%) | XXX | (15%) | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | (14%) | XXX | (34%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 0% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (23%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 11% | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 14% | XXX | 13% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 30% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Genscript Biotech Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing and Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Genscript Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Diasorin | XXX | XXX | XXX | XXX | XXX | XXX |
| Brightgene Bio-medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Sotera Health | XXX | XXX | XXX | XXX | XXX | XXX |
| MGI Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| Apeloa Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genscript Biotech M&A Activity
Genscript Biotech acquired XXX companies to date.
Last acquisition by Genscript Biotech was on XXXXXXXX, XXXXX. Genscript Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Genscript Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGenscript Biotech Investment Activity
Genscript Biotech invested in XXX companies to date.
Genscript Biotech made its latest investment on XXXXXXXX, XXXXX. Genscript Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Genscript Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Genscript Biotech
| When was Genscript Biotech founded? | Genscript Biotech was founded in 2002. |
| Where is Genscript Biotech headquartered? | Genscript Biotech is headquartered in United States. |
| How many employees does Genscript Biotech have? | As of today, Genscript Biotech has over 5K employees. |
| Is Genscript Biotech publicly listed? | Yes, Genscript Biotech is a public company listed on HKEX. |
| What is the stock symbol of Genscript Biotech? | Genscript Biotech trades under 01548 ticker. |
| When did Genscript Biotech go public? | Genscript Biotech went public in 2015. |
| Who are competitors of Genscript Biotech? | Genscript Biotech main competitors are Diasorin, Brightgene Bio-medical, Sotera Health, MGI Tech. |
| What is the current market cap of Genscript Biotech? | Genscript Biotech's current market cap is $4B. |
| What is the current revenue of Genscript Biotech? | Genscript Biotech's last 12 months revenue is $916M. |
| What is the current revenue growth of Genscript Biotech? | Genscript Biotech revenue growth (NTM/LTM) is (7%). |
| What is the current EV/Revenue multiple of Genscript Biotech? | Current revenue multiple of Genscript Biotech is 3.6x. |
| Is Genscript Biotech profitable? | Yes, Genscript Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Genscript Biotech? | Genscript Biotech's last 12 months EBITDA is $169M. |
| What is Genscript Biotech's EBITDA margin? | Genscript Biotech's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Genscript Biotech? | Current EBITDA multiple of Genscript Biotech is 19.5x. |
| What is the current FCF of Genscript Biotech? | Genscript Biotech's last 12 months FCF is $142M. |
| What is Genscript Biotech's FCF margin? | Genscript Biotech's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Genscript Biotech? | Current FCF multiple of Genscript Biotech is 23.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.